The molecular basis for EMT-mediated drug resistance could be the activation of the PI3K pathway in mesenchymal-like KRASG12C-mutant cancer cells, or, alternatively, a cell cycle alteration leading to CDK4-dependent growth [41]. Here, CDK4 is linked to cancer.